Ligufalimab and Cadonilimab in Advanced Liver Cancers

NCT06789848 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma
Refractory Hepatocellular Carcinoma
Biliary Tract Cancer

Interventions

DRUG: Ligufalimab
DRUG: Cadonilimab

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]
[object Object]